EUVIMEDEUVIMED entdecken
Crossref

IL-17/IL-17RA Axis Facilitates Immune Evasion in Hepatocellular Carcinoma by Upregulating PD-L1 via the NF-κB Pathway

Xinyang Li, Ya Wang, Chuan Shen, Ruolan Gu, Mingjie Liu, Ying Xiao, Yuexia Liu, Luyuan Ma, Caiyan Zhao iD

Digestive Diseases and Sciences · 2026-10 · 71 (10) · 5049-5062

DOI: 10.1007/s10620-026-10076-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 24.06.2026. Verfasst von Xinyang Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hebei Medical University Third Hospital, Shijiazhuang, 050000, Hebei, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Interleukin-17, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: 2026 Hebei Provincial Government Funded Project for Outstanding Clinical Medical Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The immunosuppressive tumor microenvironment in hepatocellular carcinoma (HCC) limits therapeutic efficacy. This study aimed to develop an immune-related signature for risk stratification and to identify key molecules that drive immune evasion. METHODS: Transcriptomic data from HCC were analyzed to identify immune-related genes. A prognostic risk signature was constructed using Cox and least absolute shrinkage and selection operator regression and validated in an independent external cohort. Immune cell infiltration, immune checkpoints, and interleukin (IL)-17RA expression were characterized. Serum IL-17 levels were measured in patients with HCC, patients with cirrhosis, and healthy controls. Mechanistic studies included analyses of cell proliferation, programmed death-ligand 1 (PD-L1) expression, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation, and the effects of IL-17RA knockdown. RESULTS: A six-gene risk signature stratified patients into high- and low-risk groups. The high-risk group exhibited poorer prognosis and a more immunosuppressive microenvironment. External validation confirmed model robustness, with the risk score as an independent prognostic factor (multivariable Cox, P < 0.05). IL-17RA was overexpressed in HCC and correlated with poor prognosis, immune checkpoints, and M2 macrophage infiltration. Serum IL-17 levels were elevated in patients with HCC, had diagnostic value (area under the curve [AUC] = 0.738), and predicted vascular invasion (AUC = 0.891). Mechanistically, IL-17 activated NF-κB, increased p-p65, induced p65 nuclear translocation, upregulated PD-L1, and stimulated HCC cell proliferation. Pharmacological NF-κB inhibition or genetic silencing of IL-17RA abrogated IL-17-induced PD-L1 upregulation. CONCLUSION: The six-gene prognostic signature and external validation suggest clinical utility. The IL-17/ IL-17 receptor alpha axis may drive immune escape by upregulating PD-L1 via NF-κB activation; therefore, it represents a potential prognostic biomarker and therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsInterleukin-17B7-H1 AntigenReceptors, Interleukin-17NF-kappa BTumor EscapeHumansSignal TransductionTumor MicroenvironmentFemaleUp-RegulationMalePrognosisGene Expression Regulation, NeoplasticMiddle Aged

Stichwörter der Autor:innen

Hepatocellular carcinomaIL-17IL-17RAImmunityPD-L1

Substanzen

Interleukin-17B7-H1 AntigenReceptors, Interleukin-17NF-kappa BCD274 protein, humanIL17RA protein, humanIL17A protein, human

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hebei Medical University Third Hospital, Shijiazhuang, 050000, Hebei, China.
  • Clinical Research Center for Infectious Disease of Hebei Province, Shijiazhuang, 050000, China.
  • Hebei Key Laboratory for Diagnosis, Treatment, Emergency Prevention and Control of Critical Infectious Diseases, Shijiazhuang, 050000, China.
  • Department of Infectious Diseases, Hebei Medical University Third Hospital, Shijiazhuang, 050000, Hebei, China. zhaocy@hebmu.edu.cn.
  • Clinical Research Center for Infectious Disease of Hebei Province, Shijiazhuang, 050000, China. zhaocy@hebmu.edu.cn.
  • Hebei Key Laboratory for Diagnosis, Treatment, Emergency Prevention and Control of Critical Infectious Diseases, Shijiazhuang, 050000, China. zhaocy@hebmu.edu.cn.

ORCID-Profile: Caiyan Zhao

Förderung

  • 2026 Hebei Provincial Government Funded Project for Outstanding Clinical Medical Talents

Zitieren

APA

Li, X., Wang, Y., Shen, C., Gu, R., Liu, M., Xiao, Y., Liu, Y., Ma, L., & Zhao, C. (2026). IL-17/IL-17RA Axis Facilitates Immune Evasion in Hepatocellular Carcinoma by Upregulating PD-L1 via the NF-κB Pathway. Digestive Diseases and Sciences, 71(10), 5049-5062. https://doi.org/10.1007/s10620-026-10076-8

Vancouver

Li X, Wang Y, Shen C, Gu R, Liu M, Xiao Y, et al. IL-17/IL-17RA Axis Facilitates Immune Evasion in Hepatocellular Carcinoma by Upregulating PD-L1 via the NF-κB Pathway. Digestive Diseases and Sciences. 2026;71(10):5049-5062. doi:10.1007/s10620-026-10076-8

BibTeX
@article{Li2026,
  author = {Li, Xinyang and Wang, Ya and Shen, Chuan and Gu, Ruolan and Liu, Mingjie and Xiao, Ying and Liu, Yuexia and Ma, Luyuan and Zhao, Caiyan},
  title = {IL-17/IL-17RA Axis Facilitates Immune Evasion in Hepatocellular Carcinoma by Upregulating PD-L1 via the NF-κB Pathway},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  volume = {71},
  number = {10},
  pages = {5049--5062},
  doi = {10.1007/s10620-026-10076-8}
}
Kostenlos starten →